- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.33 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 3 x C81: (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one(Non-covalent)
C81.2: 20 residues within 4Å:- Chain A: R.112, A.114, I.116, R.122, L.123, W.127, P.130, I.131, I.133, V.258, M.262, W.270, S.281, V.284, A.285, Y.288, S.290, M.294
- Chain B: V.284
- Ligands: C81.4
10 PLIP interactions:10 interactions with chain A- Hydrophobic interactions: A:W.127, A:I.131, A:I.131, A:I.133, A:V.284
- Hydrogen bonds: A:A.114, A:L.123, A:I.131, A:I.131
- Halogen bonds: A:V.258
C81.4: 17 residues within 4Å:- Chain A: L.123, I.133, H.135, I.254, V.258, W.270, C.272, N.274, Q.280, S.281, V.284
- Chain B: L.123, V.279, Q.280, V.284
- Ligands: C81.2, C81.6
5 PLIP interactions:3 interactions with chain A, 2 interactions with chain B- Hydrophobic interactions: A:V.258, A:V.284, B:V.279
- Hydrogen bonds: A:N.274, B:Q.280
C81.6: 21 residues within 4Å:- Chain B: R.112, E.113, A.114, I.116, R.122, L.123, W.127, P.130, I.131, I.133, V.258, M.262, W.270, Y.275, Q.280, S.281, V.284, Y.288, S.290, M.294
- Ligands: C81.4
11 PLIP interactions:11 interactions with chain B- Hydrophobic interactions: B:R.112, B:W.127, B:I.131, B:I.133, B:V.284
- Hydrogen bonds: B:A.114, B:L.123, B:I.131, B:I.131, B:Y.275
- Halogen bonds: B:V.258
- 2 x FLC: CITRATE ANION(Non-covalent)
FLC.3: 5 residues within 4Å:- Chain A: T.80, S.97, N.99, R.103
- Ligands: NDP.1
5 PLIP interactions:5 interactions with chain A- Hydrogen bonds: A:S.97, A:S.97, A:N.99
- Water bridges: A:T.80
- Salt bridges: A:R.103
FLC.7: 5 residues within 4Å:- Chain B: T.80, S.97, N.99, R.103
- Ligands: NDP.5
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:T.80, B:S.97, B:N.99
- Salt bridges: B:R.103
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cho, Y.S. et al., Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett (2017)
- Release Date
- 2017-11-08
- Peptides
- Isocitrate dehydrogenase [NADP] cytoplasmic: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
C
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.33 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 3 x C81: (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one(Non-covalent)
- 2 x FLC: CITRATE ANION(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cho, Y.S. et al., Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett (2017)
- Release Date
- 2017-11-08
- Peptides
- Isocitrate dehydrogenase [NADP] cytoplasmic: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
C